Oversight for clinical uses of autologous adult stem cells: lessons from international regulations
| Field | Value | Language |
| dc.contributor.author | Lysaght, T | |
| dc.contributor.author | Kerridge, I | |
| dc.contributor.author | Sipp, D | |
| dc.contributor.author | Porter, G | |
| dc.contributor.author | Capps, BJ | |
| dc.date.accessioned | 2016-05-16 | |
| dc.date.available | 2016-05-16 | |
| dc.date.issued | 2013-01-01 | |
| dc.identifier.citation | Lysaght T, Kerridge I, Sipp D, Porter G, Capps BJ. Oversight for clinical use of autologous adult stem cells: lessons from international regulations. Cell Stem Cell. 2013;13(6):647-51. | en_AU |
| dc.identifier.uri | http://hdl.handle.net/2123/14921 | |
| dc.description.abstract | Autologous adult stem cells (ASCs) are being administered by physicians for indications that have not been demonstrated as safe and effective in formal clinical trials. Examination of regulatory frameworks across five countries suggests that balancing the demands of research with clinical freedom has created structural weaknesses that are being exploited. | en_AU |
| dc.description.sponsorship | funded by the Ministry of Education, Singapore, and the Humanities and Social Sciences (HSS) Division of the Office of the Deputy President (Research and Technology) at the National University of Singapore (NUS). | en_AU |
| dc.language.iso | en | en_AU |
| dc.publisher | Elsevier | en_AU |
| dc.subject | Autologous adult stem cells (ASCs) | en_AU |
| dc.subject | stem cells | en_AU |
| dc.subject | regulatory frameworks | en_AU |
| dc.subject | clinical freedom | en_AU |
| dc.title | Oversight for clinical uses of autologous adult stem cells: lessons from international regulations | en_AU |
| dc.type | Article | en_AU |
Associated file/s
Associated collections